Supernus Pharmaceuticals | SUPN - Net Income

Stock Price
49.43
Daily Change
-1.77 -3.46%
Monthly
0.43%
Yearly
47.86%
Q2 Forecast
48.44

Supernus Pharmaceuticals reported $-2.29M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Abbott USD 1.08B 699M Mar/2026
ANI Pharmaceuticals USD 29.49M 2.86M Mar/2026
Aurora Cannabis CAD 1.82M 53.29M Dec/2025
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Canopy Growth CAD -62.63M 60.99M Dec/2025
Cara Therapeutics USD -5.53M 621K Sep/2025
Corcept Therapeutics USD -31.76M 56.05M Mar/2026
Eisai JPY 17.18B 7.02B Dec/2025
Eli Lilly USD 7.4B 760M Mar/2026
Novo Nordisk DKK 26.89B 388M Dec/2025
Pacira USD 2.92M 1.28M Mar/2026
Perrigo USD -398.6M 1.02B Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Supernus Pharmaceuticals USD -2.29M 1.81M Mar/2026
United Therapeutics USD 274.9M 89.4M Mar/2026
Xeris Pharmaceuticals USD 11.08M 10.46M Dec/2025